DB:XE7C

Stock Analysis Report

Executive Summary

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors.


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has TrovaGene's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XE7C's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-19.6%

XE7C

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

-79.1%

XE7C

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: XE7C underperformed the German Biotechs industry which returned -12.7% over the past year.

Return vs Market: XE7C underperformed the German Market which returned -20.6% over the past year.


Shareholder returns

XE7CIndustryMarket
7 Day-19.6%-0.7%-0.6%
30 Day-44.9%-12.1%-20.0%
90 Day-31.5%-22.3%-26.3%
1 Year-79.1%-79.1%-13.0%-13.2%-18.6%-20.9%
3 Year-98.9%-98.9%14.5%13.2%-19.0%-25.8%
5 Year-99.8%-99.8%-9.5%-11.8%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is TrovaGene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is TrovaGene undervalued compared to its fair value and its price relative to the market?

0.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XE7C's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XE7C's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XE7C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XE7C is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XE7C's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XE7C is good value based on its PB Ratio (0.9x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is TrovaGene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

28.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XE7C is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XE7C is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XE7C is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XE7C's revenue (70% per year) is forecast to grow faster than the German market (4% per year).

High Growth Revenue: XE7C's revenue (70% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XE7C's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TrovaGene performed over the past 5 years?

7.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XE7C is currently unprofitable.

Growing Profit Margin: XE7C is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XE7C is unprofitable, but has reduced losses over the past 5 years at a rate of 7.9% per year.

Accelerating Growth: Unable to compare XE7C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XE7C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: XE7C has a negative Return on Equity (-224.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is TrovaGene's financial position?


Financial Position Analysis

Short Term Liabilities: XE7C's short term assets ($11.4M) exceed its short term liabilities ($4.8M).

Long Term Liabilities: XE7C's short term assets ($11.4M) exceed its long term liabilities ($993.5K).


Debt to Equity History and Analysis

Debt Level: XE7C is debt free.

Reducing Debt: XE7C has no debt compared to 5 years ago when its debt to equity ratio was 175.5%.


Balance Sheet

Inventory Level: XE7C has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if XE7C's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XE7C has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XE7C has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.3% each year


Next Steps

Dividend

What is TrovaGene's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XE7C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XE7C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XE7C's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XE7C's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XE7C's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Tom Adams (76yo)

4.08s

Tenure

US$1,304,634

Compensation

Dr. Thomas H. Adams, also known as Tom, Ph.D., has been Chief Executive Officer of TrovaGene, Inc., since June 2018 and its Executive Chairman of the Board since November 2018. He served as an Interim Chie ...


CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD1.30M) is above average for companies of similar size in the German market ($USD431.53K).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Adams
Executive Chairman of the Board & CEO4.08yrsUS$1.30m0.048% $3.6k
Mark Erlander
Chief Scientific Officer7.08yrsUS$852.95k0.062% $4.7k
Brigitte Lindsay
Vice President of Finance1.25yrsno datano data
Elizabeth Anderson
VP of Finance & Administration4.75yrsno datano data
Vicki Kelemen
Vice President of Investor Relations & Clinical Development.2.25yrsno datano data

4.1yrs

Average Tenure

Experienced Management: XE7C's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Adams
Executive Chairman of the Board & CEO4.08yrsUS$1.30m0.048% $3.6k
Charles Cantor
Member of Scientific Advisory Boardno datano datano data
K. Hirth
Member of Scientific Advisory Board5.67yrsno datano data
Paul Billings
Member of Scientific Advisory Board7.42yrsUS$35.85kno data
Rodney Markin
Independent Director6.17yrsUS$159.96k0.070% $5.3k
John Brancaccio
Independent Director14.33yrsUS$159.96k0.022% $1.7k
Gary Jacob
Independent Director11.17yrsUS$139.96k0.020% $1.5k
Carlo Croce
Member of Scientific Advisory Boardno datano datano data
Riccardo Dalla-Favera
Member of Scientific Advisory Board10yrsno datano data
Brunangelo Falini
Member of Scientific Advisory Board10yrsno datano data

10.0yrs

Average Tenure

69yo

Average Age

Experienced Board: XE7C's board of directors are seasoned and experienced ( 10 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 156.4%.


Top Shareholders

Company Information

TrovaGene, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TrovaGene, Inc.
  • Ticker: XE7C
  • Exchange: DB
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.186m
  • Listing Market Cap: US$7.587m
  • Shares outstanding: 10.21m
  • Website: https://trovageneoncology.com

Number of Employees


Location

  • TrovaGene, Inc.
  • 11055 Flintkote Avenue
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TROVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2003
XE7CDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2003

Biography

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Trovagene, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 01:46
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.